A study of CLN-978 for rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rheumatoid arthritis for at least 12 weeks.
- Your rheumatoid arthritis is active, with joint swelling and a moderate to high disease activity score.
- You have tried and not responded well to at least two different types of targeted treatments (like certain pills or injectable biologics) after trying standard treatments like methotrexate.
- Blood tests show you have enough white blood cells, red blood cells, platelets, and good kidney and liver function.
- You have not had certain prior treatments like CAR-T cell therapy, anti-CD19 or anti-CD20 medicines (like rituximab) within the last 3 months, or other experimental treatments within the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This trial tests a new drug called A-319 for people with active rheumatoid arthritis (RA) that hasn't improved enough after trying other treatments. The goal is to see if A-319 can reduce joint pain, swelling, and inflammation.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
This study tests an oral drug called AP1189 for people just diagnosed with active rheumatoid arthritis who haven't yet taken standard arthritis medicines. You may be able to take part if your disease is very active and you're ready to try a new treatment option.
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
Hear when a new Rheumatoid Arthritis (RA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.